Kenneth Carl Anderson C4 Therapeutics, Inc. (CCCC) insider trading activity

Kenneth Carl Anderson is Director of C4 Therapeutics, Inc.. Currently has a direct ownership of 114,671 shares of CCCC, which is worth approximately $668,531. The most recent transaction as insider was on Jul 01, 2024, when has been sold 2,320 shares (Common Stock) at a price of $4.85 per share, resulting in proceeds of $11,252. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 115K

2.06% 3M change

11.74% 12M change

Total Value Held $668,531

Kenneth Carl Anderson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2024	BUY Grant, award, or other acquisition	$11,252 $4.85 p/Share	2,320 Added 1.98%	114,671 Common Stock
Apr 01 2024	BUY Grant, award, or other acquisition	$11,250 $8.1 p/Share	1,389 Added 1.22%	112,351 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	$11,247 $6.52 p/Share	1,725 Added 1.53%	110,962 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	$11,248 $1.7 p/Share	6,617 Added 5.71%	109,237 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	$11,252 $2.83 p/Share	3,976 Added 3.73%	102,620 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	$11,251 $3.2 p/Share	3,516 Added 3.44%	98,644 Common Stock
Jan 06 2023	BUY Exercise of conversion of derivative security	$2,527 $3.55 p/Share	712 Added 0.74%	95,128 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	$10,003 $6.38 p/Share	1,568 Added 1.63%	94,416 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$2,528 $3.55 p/Share	712 Added 0.77%	91,698 Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	$9,993 $8.69 p/Share	1,150 Added 1.22%	92,848 Common Stock
Jul 15 2022	BUY Exercise of conversion of derivative security	$5,055 $3.55 p/Share	1,424 Added 1.54%	90,986 Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	$10,005 $8.03 p/Share	1,246 Added 1.37%	89,562 Common Stock
Apr 04 2022	BUY Grant, award, or other acquisition	$9,023 $26.46 p/Share	341 Added 0.38%	88,316 Common Stock
Jan 26 2022	BUY Exercise of conversion of derivative security	$7,586 $3.55 p/Share	2,137 Added 2.37%	87,975 Common Stock
Jan 04 2022	BUY Grant, award, or other acquisition	$8,779 $31.58 p/Share	278 Added 0.32%	85,838 Common Stock
Oct 04 2021	BUY Grant, award, or other acquisition	$8,728 $44.99 p/Share	194 Added 0.23%	85,560 Common Stock
Jul 02 2021	BUY Grant, award, or other acquisition	$8,738 $39.72 p/Share	220 Added 0.26%	85,366 Common Stock
Apr 14 2021	BUY Exercise of conversion of derivative security	$2,524 $3.55 p/Share	711 Added 0.83%	85,146 Common Stock
Apr 13 2021	BUY Bona fide gift	-	2,278 Added 2.63%	84,435 Common Stock
Apr 05 2021	BUY Grant, award, or other acquisition	$8,740 $37.51 p/Share	233 Added 0.28%	82,157 Common Stock
Jan 22 2021	BUY Exercise of conversion of derivative security	$4,752 $3.07 p/Share	1,548 Added 1.85%	81,924 Common Stock
Oct 06 2020	BUY Conversion of derivative security	-	18,040 Added 18.33%	80,376 Common Stock

KCA

Kenneth Carl Anderson

Director

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Value

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

Operation

Value

Type

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC

Account